Krystal Biotech, Inc. 8-K

What Happened
Krystal Biotech (KRYS) filed an 8-K reporting that director Kirti Ganorkar notified the company on December 22, 2025 of his intent to resign from the Board of Directors. Mr. Ganorkar will continue to serve through December 31, 2025. The filing states his resignation is due to time constraints following his promotion to Managing Director at Sun Pharma and is not the result of any disagreement with the Board or management.

Key Details

• Resignation notice date: December 22, 2025; effective date: December 31, 2025.
• Reason given: increased responsibilities after promotion to Managing Director at Sun Pharma.
• No disagreement with the company’s operations, policies, or practices per the filing.
• Mr. Ganorkar served on the Board since Krystal Biotech’s IPO in September 2017.
• The 8-K was filed December 23, 2025 and signed by Chairman & CEO Krish S. Krishnan.

Why It Matters
This is a governance update that reduces Krystal Biotech’s board membership at year-end. For investors, the filing signals a voluntary, non-disruptive departure tied to the director’s outside responsibilities rather than company issues. Watch for subsequent disclosures (e.g., nominations or appointments) that could affect board composition and governance oversight.